should assess the association between hospital LOS and readmission in other types of hospitals. In children's hospitals, the majority of children may already be staying in the hospital for the appropriate amount of time. As a result, efforts to avoid readmissions should focus on other aspects of hospital discharge care. Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Comparison of Cerebral Palsy Severity Between 2 Eras of Antenatal Magnesium Use
Cerebral palsy (CP) is the leading cause of long-term childhood disability with lifetime societal and economic costs. 1 Without a cure for CP, efforts have focused on prevention and on improving function. International guidelines for early detection and intervention for CP were recently published. 2 Our institution implemented these recommendations in 2015, earlier than most clinical efforts worldwide. After publication of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM) clinical trial, 3 The American College of Obstetricians and
Gynecologists advised implementing institutional policies for magnesium sulfate administration before anticipated early preterm birth to reduce risk of CP. 4 Although BEAM did not show a reduction in the primary outcome (composite of stillbirth, infant death, and moderate or severe CP), rates of moderate or severe CP were reduced among survivors. 3 If effective, implementing this recommendation at an institutional level in 2009 should have resulted in fewer subsequent cases of moderate or severe CP at our institution.
Methods | We conducted a before-and-after cohort analysis 5 at
The Ohio State University Wexner Medical Center and Nationwide Children's Hospital in Columbus, Ohio, identifying all children born from 2002 to 2014 who received a diagnosis of CP and were delivered before 32 weeks' gestation. The fetal neuroprotection protocol implemented in 2009 matched BEAM criteria but also included preeclampsia to reflect current clinical practice. The primary outcome was CP severity assessed by the Gross Motor Function Classification System (GMFCS). 6 Secondary outcomes were CP severity assessed using the Manual Ability Classification System (MACS) and the Communication Function Classification System (CFCS). The Ohio State University Wexner Medical Center and Nationwide Children's Hospital institutional review boards approved this study and waived the need for obtaining informed patient consent owing to the retrospective nature of the study. Data analysis was conducted from June 2016 to April 2018 using SigmaPlot, version 12.5 (Systat), and Stata, version 13.0 (StataCorp). A 2-sided P < .05 was considered statistically significant. Multiple logistic regression analyses controlled for magnesium administration duration, chorioamnionitis, spontaneous or iatrogenic preterm birth, bronchopulmonary dysplasia, and age at diagnosis.
Results | Of 3736 eligible deliveries, 110 infants had CP, of which 57 (52%) received antenatal magnesium sulfate, 63 (57%) were male, and 81 (74%) were non-Hispanic white. Discussion | Our CP follow-up program enabled us to perform the largest analysis to date of antenatal magnesium exposure of preterm infants, to our knowledge. Similar to national trends, we observed adherence to magnesium administration. Our finding of decreased CP severity over time concurs with the findings of large CP registries. However, reduction in CP severity could not be attributed to magnesium. Earlier diagnosis of CP among children born after 2012 at our institution may be associated with advances in neonatal intensive care (eg, avoidance of postnatal steroids and systematic use of caffeine), but may also be due to implementation of guidelines for evidence-based early recognition of CP. Earlier diagnosis, especially before 2 years of age, may facilitate access to interventions that improve functional outcomes. Our finding may be unique to the current setting, where Administration of magnesium is a resource-intensive intervention that is not without risks. Given our findings, the role of magnesium for fetal neuroprotection may need reevaluation at the national level. Physicians should evaluate the longterm impact of clinical interventions, a mandate not unique to magnesium trials for prevention of CP. Many industries have developed lean thinking tools, such as the plan-do-checkadjust cycle, that can drive evaluation of health care recommendations adopted following large randomized trials.
